Pharmacology of Cephalexin

Introduction/Overview

Cephalexin is a first-generation cephalosporin antibiotic that has maintained a significant role in clinical practice since its introduction. Its development represented a pivotal advancement in antimicrobial therapy, offering a broader spectrum of activity and improved stability compared to earlier beta-lactam agents. The clinical relevance of cephalexin stems from its reliable activity against common Gram-positive pathogens, favorable safety profile, and convenient oral formulation, making it a cornerstone agent for outpatient management of various bacterial infections. Its importance is underscored by its continued inclusion in treatment guidelines for skin and soft tissue infections, respiratory tract infections, and uncomplicated urinary tract infections, particularly in the context of increasing antimicrobial resistance.

Learning Objectives

• Describe the chemical classification of cephalexin and its relationship to other beta-lactam antibiotics.
• Explain the molecular mechanism of action by which cephalexin inhibits bacterial cell wall synthesis.
• Analyze the pharmacokinetic profile of cephalexin, including absorption, distribution, metabolism, and excretion characteristics.
• Identify the primary clinical indications for cephalexin therapy and recognize appropriate dosing regimens based on patient-specific factors.
• Evaluate the major adverse effects, drug interactions, and special considerations necessary for the safe and effective use of cephalexin.

Classification

Cephalexin belongs to the cephalosporin class of antibiotics, which are beta-lactam antimicrobials structurally and functionally related to penicillins. More specifically, it is classified as a first-generation cephalosporin. This generational classification is based primarily on the spectrum of antimicrobial activity, with first-generation agents exhibiting potent activity against Gram-positive cocci and more limited activity against Gram-negative organisms compared to later generations.

Chemical Classification

Chemically, cephalexin is a semisynthetic derivative of cephalosporin C. Its core structure consists of a beta-lactam ring fused to a six-membered dihydrothiazine ring, forming the 7-aminocephalosporanic acid nucleus. This beta-lactam-dihydrothiazine bicyclic system is fundamental to its antibacterial activity. The chemical structure includes specific R-group substitutions at the 7-position of the beta-lactam ring, which confer stability against certain bacterial beta-lactamases, and at the 3-position, which influences pharmacokinetic properties. Cephalexin is the D-5-methyl-2-cyclohexadienylglycyl analogue of cephaloglycin. It is formulated as a monohydrate crystalline powder and is highly soluble in water. The molecular formula is C₁₆H₁₇N₃O₄S·H₂O, with a molecular weight of 365.41 g/mol.

Mechanism of Action

The antibacterial effect of cephalexin, like other beta-lactam antibiotics, is primarily bactericidal and results from the inhibition of bacterial cell wall synthesis. This action is exerted during the active growth and multiplication phase of susceptible bacteria.

Molecular and Cellular Mechanisms

Cephalexin’s mechanism is initiated by its penetration through the outer layers of the bacterial cell. In Gram-positive bacteria, which lack a complex outer membrane, cephalexin diffuses easily through the porous peptidoglycan layer to reach its target. In Gram-negative bacteria, access to the target site is more restricted and relies on diffusion through porin channels in the outer membrane.

The primary molecular target is a group of enzymes known as penicillin-binding proteins (PBPs). These membrane-bound bacterial enzymes are transpeptidases, carboxypeptidases, and endopeptidases that catalyze the final cross-linking steps in the assembly of the peptidoglycan polymer, which provides structural integrity to the cell wall. Cephalexin, with its beta-lactam ring, acts as a structural analogue of the D-alanyl-D-alanine terminus of the pentapeptide side chains of the nascent peptidoglycan. The beta-lactam ring is highly reactive due to ring strain and the amide bond’s susceptibility to nucleophilic attack.

Cephalexin binds covalently and irreversibly to the active serine site of the PBPs. This acylation reaction involves the nucleophilic hydroxyl group of the serine residue attacking the carbonyl carbon of the beta-lactam amide bond, leading to ring opening and the formation of a stable, inactive acyl-enzyme complex. The inactivation of these essential enzymes disrupts the transpeptidation reaction, preventing the formation of the cross-links between the linear glycan strands. Consequently, the bacterial cell wall is weakened and unable to withstand the internal osmotic pressure, leading to cell lysis and death. The bactericidal effect is considered to be time-dependent, meaning the duration of time the drug concentration remains above the minimum inhibitory concentration (MIC) for the pathogen is the critical pharmacokinetic/pharmacodynamic index correlating with efficacy.

Spectrum of Activity

The spectrum of antibacterial activity is a defining characteristic of first-generation cephalosporins. Cephalexin demonstrates potent in vitro activity against a range of Gram-positive cocci. This includes beta-hemolytic streptococci (e.g., Streptococcus pyogenes), Streptococcus pneumoniae (penicillin-susceptible strains), and methicillin-susceptible Staphylococcus aureus (MSSA). It is important to note that cephalexin is not active against methicillin-resistant Staphylococcus aureus (MRSA), enterococci, or penicillin-resistant Streptococcus pneumoniae. Its activity against Gram-negative bacteria is more limited but includes some strains of Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis. It lacks reliable activity against Haemophilus influenzae, Enterobacter species, Pseudomonas aeruginosa, Serratia, and Bacteroides fragilis.

Pharmacokinetics

The pharmacokinetic profile of cephalexin is characterized by excellent oral bioavailability, minimal metabolism, and primarily renal elimination, which guides its dosing and clinical application.

Absorption

Cephalexin is rapidly and nearly completely absorbed from the gastrointestinal tract following oral administration. Its absorption occurs primarily in the duodenum and upper jejunum. Bioavailability is estimated to be approximately 90% or greater under fasting conditions. The presence of food in the gastrointestinal tract may delay the rate of absorption, slightly prolonging the time to reach peak serum concentration (T_max), but does not significantly reduce the total extent of absorption (AUC). Peak serum concentrations (C_max) are typically achieved within 1 hour of administration. For a standard 500 mg dose, the mean C_max is approximately 18 µg/mL. The absorption process is not saturable within the therapeutic dosing range.

Distribution

Cephalexin distributes widely into most body tissues and fluids. It achieves therapeutic concentrations in kidneys, bone, synovial fluid, pleural fluid, and bile. However, its penetration into the cerebrospinal fluid (CSF) is poor, even in the presence of inflamed meninges, rendering it unsuitable for the treatment of meningitis. The volume of distribution (V_d) is approximately 0.26 L/kg, indicating distribution primarily within the extracellular fluid compartment. Protein binding is relatively low, reported to be between 10% and 15%, primarily to albumin. This low degree of protein binding suggests that the concentration of pharmacologically active, unbound drug in plasma is high and that displacement interactions with other highly protein-bound drugs are unlikely to be clinically significant.

Metabolism

Cephalexin undergoes minimal hepatic metabolism. More than 90% of an administered dose is excreted unchanged in the urine within 8 hours. A very small fraction may be metabolized, but this does not contribute meaningfully to its activity or elimination. The lack of significant hepatic metabolism reduces the potential for pharmacokinetic interactions involving hepatic enzyme induction or inhibition.

Excretion

Renal excretion is the principal route of elimination for cephalexin. The drug is eliminated predominantly by glomerular filtration, with some contribution from active tubular secretion. The renal clearance of cephalexin exceeds the glomerular filtration rate, indicating the involvement of an active secretory mechanism. In individuals with normal renal function, the elimination half-life (t_1/2) ranges from 0.5 to 1.2 hours. Because excretion is so heavily dependent on renal function, the half-life increases proportionally as creatinine clearance declines. In anuric patients, the half-life may be prolonged to 20–30 hours. Hemodialysis effectively removes cephalexin from the circulation, a fact that must be considered when dosing patients undergoing such procedures.

Pharmacokinetic Parameters and Dosing Considerations

The short half-life of cephalexin necessitates multiple daily dosing to maintain serum concentrations above the MIC for susceptible pathogens for a sufficient duration. Dosing intervals are typically every 6 to 12 hours, depending on the severity of the infection. For most indications, a regimen of 250 mg to 500 mg administered every 6 hours is standard. In pediatric populations, dosing is based on body weight, typically 25 to 50 mg/kg/day divided into four doses. The relationship between dose and resulting serum concentration is linear. Given its renal elimination, dosage adjustment is mandatory in patients with impaired renal function. A common guideline is to administer a standard loading dose, followed by reduced maintenance doses or extended dosing intervals based on the patient’s estimated creatinine clearance.

Therapeutic Uses/Clinical Applications

Cephalexin is indicated for the treatment of bacterial infections caused by susceptible strains of designated microorganisms. Its use should be guided by clinical presentation, likely pathogens, and local antimicrobial resistance patterns.

Approved Indications

• Respiratory Tract Infections: Cephalexin is effective for treating pharyngitis and tonsillitis caused by Streptococcus pyogenes. It serves as an alternative for patients with penicillin hypersensitivity (excluding immediate-type reactions). It may also be used for lower respiratory tract infections such as bronchitis and community-acquired pneumonia when caused by susceptible Streptococcus pneumoniae.
• Skin and Skin Structure Infections: This is a major indication for cephalexin. It is commonly prescribed for uncomplicated cellulitis, impetigo, folliculitis, furuncles, and carbuncles caused by MSSA or Streptococcus pyogenes.
• Bone and Joint Infections: Cephalexin can be used for the oral step-down therapy of osteomyelitis or septic arthritis caused by susceptible staphylococci or streptococci, following initial intravenous antibiotic treatment.
• Genitourinary Tract Infections: It is indicated for acute uncomplicated cystitis and other urinary tract infections caused by susceptible strains of Escherichia coli, Proteus mirabilis, and Klebsiella species. Its utility in pyelonephritis is more limited due to the potential for resistant pathogens.
• Otitis Media: Cephalexin may be used for acute otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, staphylococci, and streptococci, though its efficacy against H. influenzae is variable and other agents are often preferred.

Off-Label Uses

Several off-label applications are supported by clinical experience and some evidence. These include surgical prophylaxis for clean-contaminated procedures involving the oropharynx or skin, particularly in penicillin-allergic patients. It is sometimes used for the prophylaxis of recurrent cellulitis in patients with chronic lymphedema. In dental practice, it may be employed for prophylaxis against infective endocarditis in at-risk patients with penicillin allergy, although guidelines should be consulted for current recommendations. Its use in the management of mild to moderate diabetic foot infections, as part of a broader treatment plan, has also been documented.

Adverse Effects

Cephalexin is generally well-tolerated, with most adverse effects being mild and self-limiting. The incidence of serious adverse reactions is low.

Common Side Effects

Gastrointestinal disturbances are the most frequently reported adverse effects, occurring in approximately 2-5% of patients. These include diarrhea, nausea, vomiting, dyspepsia, and abdominal pain. The diarrhea associated with cephalexin is often mild and may be related to alterations in gut flora. Oral and vaginal candidiasis (thrush) can occur due to suppression of normal flora. Other common effects involve hypersensitivity reactions, which are typically cutaneous in nature, such as maculopapular rash, urticaria, and pruritus. These rashes are more common in patients with a history of penicillin allergy, though the cross-reactivity rate between penicillins and first-generation cephalosporins like cephalexin is estimated to be low, approximately 1-3%, and is primarily a concern for patients with a history of immediate-type IgE-mediated reactions (e.g., anaphylaxis, angioedema). Headache, dizziness, and fatigue have also been reported.

Serious and Rare Adverse Reactions

Although uncommon, several serious adverse reactions require prompt recognition and discontinuation of therapy.

• Clostridioides difficile-Associated Diarrhea (CDAD): Antibiotic use, including cephalexin, can disrupt colonic flora, potentially leading to overgrowth of toxigenic Clostridioides difficile. This may range from mild diarrhea to life-threatening pseudomembranous colitis. CDAD can occur during or several weeks after antibiotic therapy.
• Severe Hypersensitivity Reactions: Anaphylaxis, though rare, is a medical emergency. Symptoms may include laryngeal edema, bronchospasm, hypotension, and cardiovascular collapse. Stevens-Johnson syndrome and toxic epidermal necrolysis are severe cutaneous adverse reactions that are exceedingly rare but potentially fatal.
• Hematologic Effects: Transient neutropenia, leukopenia, thrombocytopenia, and eosinophilia have been reported. Hemolytic anemia, sometimes associated with a positive direct Coombs’ test, is a rare complication.
• Renal Effects: Interstitial nephritis, presenting with fever, rash, eosinophilia, and elevated serum creatinine, is a potential adverse effect. This is typically reversible upon discontinuation of the drug.
• Hepatobiliary Effects: Mild, transient elevations in liver transaminases and alkaline phosphatase can occur. Cholestatic jaundice is a rare event.
• Central Nervous System Effects: Reversible hyperactivity, agitation, anxiety, insomnia, confusion, and hallucinations have been reported, particularly in elderly patients or those with renal impairment where drug accumulation can occur.

Black Box Warnings

Cephalexin does not carry a black box warning from regulatory authorities such as the U.S. Food and Drug Administration. However, the class-wide risk of CDAD is prominently highlighted in prescribing information.

Drug Interactions

The potential for clinically significant drug interactions with cephalexin is relatively limited due to its minimal metabolism and low protein binding. However, several interactions warrant consideration.

Major Drug-Drug Interactions

• Probenecid: Probenecid competitively inhibits the active tubular secretion of cephalexin in the kidneys. This interaction decreases the renal clearance of cephalexin, leading to increased and prolonged serum concentrations. While this can be exploited therapeutically to enhance drug levels, it may also increase the risk of adverse effects, particularly in patients with renal impairment.
• Metformin: Coadministration of cephalexin with metformin may competitively inhibit the renal tubular secretion of metformin, potentially increasing metformin plasma concentrations and the risk of lactic acidosis. Close monitoring of blood glucose and renal function is advisable.
• Oral Anticoagulants (Warfarin): Some cephalosporins that contain an N-methylthiotetrazole (NMTT) side chain can interfere with vitamin K metabolism and potentiate the effects of warfarin. Although cephalexin lacks this side chain and a direct pharmacokinetic interaction is unlikely, any antibiotic can alter gut flora and potentially affect vitamin K synthesis, which may theoretically influence anticoagulant control. Monitoring of the International Normalized Ratio (INR) is prudent during concurrent therapy.
• Other Nephrotoxic Agents: Concurrent use with drugs known to be nephrotoxic, such as aminoglycosides (e.g., gentamicin), potent diuretics (e.g., furosemide), or nonsteroidal anti-inflammatory drugs (NSAIDs), may increase the risk of renal dysfunction. Renal function should be monitored.

Contraindications

The primary contraindication to cephalexin use is a history of a serious hypersensitivity reaction to cephalexin itself or any other cephalosporin antibiotic. A history of an immediate-type IgE-mediated allergic reaction (e.g., anaphylaxis, angioedema, urticaria) to any penicillin is generally considered a relative contraindication due to the potential for cross-reactivity, and alternative antibiotics from a different class should be strongly considered.

Special Considerations

Safe and effective use of cephalexin requires attention to specific patient populations and physiological conditions.

Use in Pregnancy and Lactation

Cephalexin is classified as Pregnancy Category B in the former FDA classification system, indicating that animal reproduction studies have not demonstrated a fetal risk, but adequate and well-controlled studies in pregnant women are lacking. It has been used extensively during pregnancy without a clear signal of teratogenicity. It should be used during pregnancy only if clearly needed. Cephalexin is excreted in human milk in low concentrations. While adverse effects on the nursing infant are unlikely, caution is advised. Potential effects on the infant’s gastrointestinal flora and the possibility of hypersensitivity reactions should be considered.

Pediatric Considerations

Cephalexin is commonly used in pediatric populations for appropriate indications such as otitis media, streptococcal pharyngitis, and skin infections. Dosage is based on body weight (mg/kg/day), typically divided into four doses. The suspension formulation must be shaken well before each use to ensure accurate dosing. Monitoring for gastrointestinal side effects and candidiasis is recommended.

Geriatric Considerations

Elderly patients are more likely to have age-related reductions in renal function. Since cephalexin is eliminated renally, dosage adjustments based on estimated creatinine clearance are often necessary to prevent drug accumulation and potential toxicity, including central nervous system effects. A lower initial dose or extended dosing interval may be appropriate. Comorbid conditions and concomitant medications should be reviewed for potential interactions.

Renal Impairment

Dosage adjustment is essential in patients with renal impairment to prevent excessive drug accumulation. After an initial loading dose, the maintenance dose should be reduced, or the dosing interval prolonged. Specific guidelines are available based on creatinine clearance (CrCl):

• CrCl 30-59 mL/min: Maximum dose of 500 mg every 8-12 hours.
• CrCl 15-29 mL/min: Maximum dose of 250-500 mg every 12-24 hours.
• CrCl 5-14 mL/min: Maximum dose of 250-500 mg every 24-48 hours.
• CrCl < 5 mL/min: Maximum dose of 250-500 mg every 48-96 hours.

Patients on hemodialysis typically receive a dose after each dialysis session, as the drug is effectively removed.

Hepatic Impairment

No specific dosage adjustment is required for hepatic impairment alone, as cephalexin is not significantly metabolized by the liver. However, in patients with combined hepatic and renal dysfunction, careful monitoring is warranted.

Summary/Key Points

• Cephalexin is a first-generation oral cephalosporin antibiotic with a bactericidal mechanism of action involving irreversible inhibition of penicillin-binding proteins, leading to disruption of bacterial cell wall synthesis.
• Its antimicrobial spectrum is characterized by reliable activity against methicillin-susceptible Staphylococcus aureus and streptococci, with more limited activity against common Gram-negative organisms.
• Pharmacokinetically, it is well-absorbed orally, distributes widely into tissues (excluding the CNS), undergoes minimal metabolism, and is excreted unchanged primarily via renal mechanisms, resulting in a short half-life that necessitates multiple daily dosing.
• Primary clinical applications include the treatment of skin and soft tissue infections, respiratory tract infections, uncomplicated urinary tract infections, and bone/joint infections caused by susceptible organisms.
• The drug is generally well-tolerated, with gastrointestinal disturbances and mild hypersensitivity reactions being the most common adverse effects. Serious risks include Clostridioides difficile-associated diarrhea and severe hypersensitivity reactions.
• Significant drug interactions are few but include probenecid and potential interactions with metformin and nephrotoxic agents. Dosage adjustment is mandatory in renal impairment.

Clinical Pearls

• Cephalexin is not effective against MRSA, enterococci, or penicillin-resistant pneumococci. Culture and susceptibility testing should guide therapy when possible.
• In patients reporting a penicillin allergy, the cross-reactivity risk with cephalexin is low (≈1-3%) but is highest for those with a history of immediate-type reactions (anaphylaxis). A thorough allergy history is critical.
• For optimal absorption and to minimize gastrointestinal upset, cephalexin can be administered with food, though this may slightly delay the time to peak concentration.
• Patients should be instructed to complete the entire prescribed course of therapy, even if symptoms improve, to prevent relapse and the development of antibiotic resistance.
• Monitoring for signs of superinfection (e.g., oral or vaginal candidiasis) and C. difficile diarrhea (watery stools, abdominal cramping) is an important component of patient counseling and follow-up.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
4. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
5. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.